You are now leaving the Lilly Medical website
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Kisunla ™ (donanemab-azbt) injection, for intravenous infusion
350 mg/20 mL (17.5 mg/mL)
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
How is Kisunla™ (donanemab-azbt) metabolized and excreted?
Kisunla (donanemab) is expected to be degraded by proteolytic enzymes in the same manner as endogenous IgG.
See important safety information, including boxed warning, in the attached prescribing information.
Additional Information Regarding Metabolism and Elimination
Donanemab is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody and is expected to be degraded by proteolytic enzymes in the same manner as endogenous IgG.1
As such, donanemab is not expected to
- inhibit metabolic or induce enzymatic pathways
- be metabolized by the cytochrome P450 families of drug-metabolizing enzymes, or
- produce any active metabolites.2
Donanemab has a
- half-life of approximately 12.1 days, and
- clearance of 0.0255 L/h.1
Enclosed Prescribing Information
References
1Kisunla [package insert]. Indianapolis, IN: Eli Lilly and Company; 2024.
2Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Date of Last Review: December 07, 2023